Hydrogels based on collagen and fibrin - Frontiers and applications by Schneider-Barthold, Caroline et al.
BioNanoMat 2016; 17(1-2): 3–12
aCaroline Schneider-Barthold and Sabrina Baganz: These authors 
contributed equally to this publication.
*Corresponding author: Dr. Iliyana Pepelanova, Institute of 
Technical Chemistry, Leibniz University Hannover, Callinstraße 5, 
30167 Hannover, Germany, Phone: +49 (0) 511 762 2381,  
E-mail: pepelanova@iftc.uni-hannover.de
Caroline Schneider-Barthold, Sabrina Baganz and Thomas Scheper: 
Institute of Technical Chemistry, Leibniz University Hannover, 
Callinstraße 5, 30167 Hannover, Germany
Mathias Wilhelmi: Department of Cardiothoracic, Medical University 
Hannover, Transplantation and Vascular Surgery, Carl-Neuberg-Str. 
1, 30625 Hannover, Germany
Review
Caroline Schneider-Bartholda, Sabrina Baganza, Mathias Wilhelmi, Thomas Scheper 
and Iliyana Pepelanova*
Hydrogels based on collagen and fibrin – frontiers 
and applications
DOI 10.1515/bnm-2015-0025
Received December 21, 2015; accepted March 21, 2016
Abstract: Hydrogels are a versatile tool for a multitude of 
applications in biomedical research and clinical practice. 
Especially collagen and fibrin hydrogels are distinguished 
by their excellent biocompatibility, natural capacity for 
cell adhesion and low immunogenicity. In many ways, 
collagen and fibrin represent an ideal biomaterial, as 
they can serve as a scaffold for tissue regeneration and 
promote the migration of cells, as well as the ingrowth of 
tissues. On the other hand, pure collagen and fibrin mate-
rials are marked by poor mechanical properties and rapid 
degradation, which limits their use in practice. This paper 
will review methods of modification of natural collagen 
and fibrin materials to next-generation materials with 
enhanced stability. A special focus is placed on biomedical 
products from fibrin and collagen already on the market. 
In addition, recent research on the in vivo applications of 
collagen and fibrin-based materials will be showcased.
Keywords: biohybrid polymer; clinical application; struc-
tural proteins; tissue engineering.
Introduction
The first hydrogels used in the biomedical context 
appeared in the 1970s, when the need for a new material 
for cell cultivation was high. Complex reactions in a tis-
sue-like system could not be properly investigated at the 
time. Materials like collagen, alginate and carrageenan 
were used as an immobilization matrix for fibroblasts 
[1] and microbial cells [2, 3]. Langer and Vacanti gave an 
overview of the first hydrogels in tissue engineering [4]. 
The application of hydrogel scaffolds in tissue engineer-
ing and biomedicine has taken great steps since then [5].
Classical hydrogels with excellent biocompatibility 
and bioactivity are natural, protein-based polymers like 
collagen [6], gelatine [7], silk fibroin and fibrin [8]. Espe-
cially proteins from the extracellular matrix (ECM) like 
collagen or fibrin are promising candidates in the field of 
tissue implants due to their ability to mimic key biochemi-
cal factors vital for tissue regeneration. Fibrin plays an 
important role in wound healing, hemostasis and angio-
genesis, and serves as a provisional matrix. Collagen, as 
a major constituent of the ECM, adds to the mechanical 
strength and flexibility of different tissues, and contains 
important RGD binding sites. The ECM serves as the 
mechanical framework for cells and tissues by providing 
adhesion molecules and growth factors. The fibrin matrix 
during wound healing provides attachment sites for cells, 
which in turn lay out a novel extracellular matrix, com-
posed predominantly of collagen. Both proteins serve as 
a scaffold for tissue regeneration and can promote the 
migration and ingrowth of cells. Fibrin and collagen are 
an ideal biomaterial for hydrogel scaffolds, because of 
their distinguished biocompatibility and cell adhesion 
capability [9, 10].
The formation of a hydrogel from fibrin is based on its 
natural polymerization process with thrombin following 
vascular injury. Thrombin cleaves two small amino acid 
sequences in the amino-termini of the Aα and Bβ chain of 
the fibrin precursor fibrinogen. As a consequence, polym-
erization sites within the molecule are exposed, which 
leads to the polymerization of single fibrinogen molecules 
to a 3D fibrin network. Further stabilization of this network 
is achieved by covalent crosslinking which is catalyzed 
by factor XIIIa (as reviewed in [11]). Polymerization can 
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be influenced by temperature, as well as thrombin and 
fibrinogen concentrations [12, 13]. Increased mechanical 
stability can be achieved by casting techniques leading to 
a compacted fibrin matrix [14]. It should be noted that the 
fibrinogen material for biomedical research is typically 
sourced from blood, which always carries a residual risk 
of pathogen transmission.
Native collagen polymerizes into fibrils on its own 
[15]. When using extracted collagen, a fibrillar scaffold 
similar to the ECM can be formed by increasing the pH 
and temperature of the collagen solution. Collagen bioma-
terial can be obtained from a variety of natural sources. 
The most common materials are from a bovine or porcine 
origin [16] but also discarded human tissue (e.g. placenta) 
provides a good source of collagen [17]. As the extraction 
of biomedical material from mammalian tissue is always 
accompanied by concerns about the safety of the mate-
rial, new sources have received attention in recent years. 
These include poultry as well as marine sources of col-
lagen like fish, shark, jellyfish and marine sponges [18]. 
However, the production of collagen from these sources 
is still limited.
Despite the fact that collagen and fibrin-based hydro-
gels are already widespread in clinical applications, in 
practice they display some disadvantages like mechanical 
instability [14, 19] or in the case of fibrin gels, rapid deg-
radation [20]. To overcome these drawbacks, more stable 
materials can be achieved by blending with natural and 
synthetic polymers or by influencing the crosslink density. 
The resulting materials combine the inherent bioactivity 
of collagen and fibrin with tailor-made mechanical prop-
erties. More detailed information about the classification 
of hydrogel materials and the preparation of hydrogels can 
be found in recent reviews [21, 22]. In this paper, we will 
give an overview of modifications of collagen and fibrin 
hydrogels with natural and synthetic polymers leading 
to augmentation of mechanical properties. In addition, 
we review current commercial biomedical applications of 
fibrin and collagen gels, as well as recent research of in 
vivo applications.
Modifications for enhanced stability
Overcoming the mechanical instability yet preserving the 
excellent biocompatibility of protein-based hydrogels is 
the main focus of the modification process. Their natural 
origin leaves the proteins susceptible to protease degra-
dation, which can be advantageous in the case of a bio-
degradable matrix, but also a limitation, if the scaffold 
structure is being degraded too fast for tissue regenera-
tion. Some instability issues can be counteracted with 
a higher concentration of polymer in the gel, but atten-
tion has to be paid to the resulting pore size. Higher con-
centrated gels form a dense network which impedes cell 
migration and ingrowth into the matrix [23, 24]. Lower 
concentrated gels have poor mechanical properties and 
may tear easily during implantation. The general chal-
lenge for designing hydrogels is the balancing act between 
providing a cell-promoting environment and having good 
mechanical properties.
There are several possibilities of modifying natural 
protein hydrogels. Stabilization can be achieved by blend-
ing with natural or synthetic polymers, as well as chemi-
cal crosslinking. Alternative strategies include using 
composites like interpenetrating polymer networks (IPNs) 
or semi-IPNs. IPNs are formed when polymer monomers 
are polymerized within a pre-polymerized network. Semi-
IPNs are formed when linear polymers are entrapped 
within a pre-polymerized hydrogel [25]. In IPNs or semi-
IPNs only physical interactions and no chemical interac-
tions occur [26].
Here, we focus on modifications for enhanced stabil-
ity through the addition of different natural and synthetic 
polymers or some form of crosslinking manipulation. We 
do not review modifications aimed primarily at bioactiv-
ity enhancement, such as those with adhesion peptides 
or heparin.
Modification with natural components
Collagen and fibrin can be modulated into a stronger 
hydrogel by combining them [27]. It has been shown 
that composites of different concentrations of collagen 
and fibrin display increased compaction, which leads to 
mechanically robust matrices. Of all composites tested, 
the construct with 1:1 collagen to fibrin ratio correspond-
ing to a total protein concentration of 1 mg/mL, resulted 
in the highest cell concentration (cell number combined 
with gel compaction) and best mechanical properties 
[material modulus of 52.2 kPa in contrast to 11.2 kPa 
(pure collagen) and 21.9 kPa (pure fibrin)] [27]. This result 
is supported by other studies, which also proved that a 
composite of collagen and fibrin possesses enhanced 
mechanical features compared to pure collagen and pure 
fibrin alone [28, 29]. Other natural components can be 
used to modify fibrin, as well as collagen in order to stabi-
lize the protein gels. These include chitosan, hyaluronic 
acid and genipin. Chitosan-modified protein gels form 
stable scaffolds with enhanced mechanical features and 
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are a promising biomaterial to be used as a wound dress-
ing. Collagen sponges crosslinked with chitosan and 
embedded with human acidic fibroblast growth factor led 
to improved diabetic wound healing [30]. Membranes fab-
ricated from collagen and chitosan were functionalized 
with silver. The result was a film with a diffusion coef-
ficient similar to human cornea. Additionally, the silver 
ions led to bactericidal activation of the scaffold, but also 
caused a small degree of hemolysis [31]. Another modi-
fication with chitosan is a composite of fibrin, chitosan 
and sodium alginate used for veterinary wound healing 
[32]. It showed enhanced mechanical features, because of 
the ionic bond between the amine groups of the chitosan 
and the carboxyl groups of the alginate.
Using hyaluronic acid with fibrin and collagen is 
another successful strategy for improving the mechanical 
stability of protein-based hydrogels. Fibrin and hyaluronic 
acid (HA) with methacrylic anhydride (MA) form stable 
hydrogels with enhanced mechanical strength, which 
could be correlated to increasing HA-MA concentrations 
[33]. Furthermore, gene expression studies proved that 
proliferation of bone marrow-derived mesenchymal stem 
cells and even differentiation into chondrocytes was pro-
moted by this composite. Hyaluronic acid can be modified 
with tyramine (tyr) to produce hyaluronic acid-tyramine 
polymers, which in turn can be used as a modification for 
fibrin networks. The formation of a hydrogel consisting of 
fibrin and HA-tyr led to improved structural stability due 
to the mechanical support provided by the modified hya-
luronic acid [34].
Modification of the structural proteins fibrin and col-
lagen with genipin, a natural aglycone, also resulted in 
mechanically stronger hydrogels. Two approaches were 
taken to crosslinking fibrin with genipin which showed 
slightly different results. First, crosslinking was performed 
after the gelation process was finished. The resulting gel 
had a high crosslinking density and was stable for a long 
time. The second method used crosslinking and gelation 
at the same time and resulted in a gel with enhanced 
mechanical features [35]. The second approach is more 
suitable for tissue engineering as the mechanical proper-
ties can be modulated at the same time the cell encapsu-
lation takes place. Furthermore, genipin decreased the 
proteolytic degradation of the fibrin network [36].
Examples for polysaccharides combined with collagen 
to form stable hydrogels are alginate, glycosaminoglycans, 
cellulose and dextran. The modification of collagen with 
alginate-dialdehyde led to a stabilized collagen matrix and 
also to a denser network structure. The resulting hydrogel 
promoted cell attachment and proliferation [37]. Copoly-
merization with glycosaminoglycans resulted in a stiffer 
and tougher hydrogel with a decreased degradation rate 
of collagen [38]. Glycosaminoglycan-modified collagen 
type I hydrogels are already used in a variety of in vivo and 
in vitro applications [39]. Oxidized glycosaminoglycans 
have been investigated by Zhao et al. who proved that they 
have no negative effect on cell behavior [40]. Dialdehyde 
carboxymethyl cellulose (DCMC) as a crosslinker of colla-
gen improved the thermal stability of collagen and did not 
interfere with the triple helical structure of the molecules 
[41]. Thermal stability enhancement was also the result 
of collagen gels modified with aldehyde-functionalized 
dextran (DAD). The maximum compressive strength of the 
collagen-DAD gels was about 20 times higher than that of 
a pure collagen hydrogel [42].
Proteins can also be utilized to modify collagen gels, 
e.g. it was shown that soy protein had a strengthening 
effect on the gel and was well distributed in the network 
[43]. Modifications at the amino acid level of collagen can 
alternate the structure of the protein and lead to favorable 
changes. The use of D-alanine in the amino acid sequence 
of collagen led to conformational changes and thus inhib-
ited collagenase activity at the cleavage site [44].
Biohybrid fibrin and collagen hydrogels
Modification with natural materials does not always lead 
to the desired result of a mechanically stable and biologi-
cally active hydrogel. On the other hand, synthetic hydro-
gels do not carry natural binding sites for cells which 
hinders their usage in tissue engineering. As a result, com-
binations of synthetic polymers and natural proteins are 
an attractive option for certain applications. The resulting 
hydrogels display great mechanical strength and it is pos-
sible to modify their physicochemical characteristics in a 
controllable way.
Polyvinyl alcohol (PVA) is a biocompatible molecule 
which shows good mechanical properties [45] and the 
ability to simulate natural tissues [46]. Pure PVA gels 
display no degradation [47] and cell membrane protein 
binding occurs to a low extent only [21]. Bidault et  al. 
showed that the storage modulus of a (methylacrylated)-
PVA-fibrin-IPN was 3–50-fold higher in comparison to 
pure fibrin gels [45]. Furthermore, they have proven that 
the biohybrid material is non-cytotoxic. However, no cell 
proliferation of human fibroblasts was observed. In 2015 
the same research group improved cell growth and bio-
degradability by introducing (methylacrylated)-serum 
albumin to the PVA-fibrin-IPN [47]. A combination of 
collagen and PVA improved the compressive strength of 
the pure hydrogels. By crosslinking collagen and PVA 
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with glutaraldehyde, the compressive strength could be 
increased even further [48].
Another attractive modification is the usage of poly-
ethylene glycol (PEG): a biocompatible, biodegradable 
polymer which is inert to cell or protein adsorption [49]. 
PEG can be modified with fibrin(ogen) or collagen in 
various ways leading to increased mechanical strength 
in all cases. For example, one approach described in the 
literature is the encapsulation of fibrin ribbons into a PEG 
hydrogel [50]. Another group, Jiang et  al., loaded fibrin 
into a porous PEG hydrogel resulting in a decreased deg-
radation rate of fibrin, which in turn induced vascularized 
tissue ingrowth due to the prolonged fibrin lifetime [51]. 
Collagen can be modified with PEG in a semi-IPN leading 
to higher viscoelasticity and elongation. Furthermore, 
cell adhesion and cell proliferation was promoted in this 
composite, which makes it a good scaffold for viscoelastic 
tissues [52].
Instead of using pure components, one could 
use PEGylated hydrogel-precursors for modification. 
PEGylated precursors are made by crosslinking dena-
tured fibrinogen and collagen [the latter being modified 
with succinimidylacetyl-thioacetate (SATA)] to PEG. Pho-
topolymerization of these PEGylated precursors leads to 
scaffolds which enable migration, cell spreading and con-
trollable proteolytic degradation [53]. Stabenfeldt et  al. 
examined the influence of synthetic PEGylated fibrin knob 
peptides on the polymerization process and the resulting 
mechanical properties of the fibrin gels. An increase of the 
complex moduli, porosity and a decrease in the degrada-
tion rate could be observed when a fibrin knob ‘B’ peptide 
was used [54].
Fibrin and collagen can also be modified with poly-
lactic acids. For example, porous polylactic acid can be 
filled with a fibrin gel. Zhao et al. decelerated the weight 
loss rate of fibrin with such a polylactic acid construct 
[55]. A combination of poly lactic-co-glycolic acid, poly-
lactic acid and fibrin achieved mechanical stability and a 
stable construct size during cultivation [56]. Porous col-
lagen was also modified with surface activated polylactic 
acid fibers [57] or nanoparticles [58] leading in both cases 
to an increase in the compression modulus.
Another promising approach in research are thermo-
sensitive hydrogels based on collagen and fibrin in combi-
nation with the Pluronic® F127 copolymer. Pluronic® F127 
copolymer undergoes reverse thermal gelation in response 
to temperature changes. The conjugation of fibrinogen to 
Pluronic® F127 enables the control over physical proper-
ties (variable G′ and G″ values) while retaining full cell 
compatibility of the hybrid hydrogel [59]. The combina-
tion of collagen with Pluronic® F127 led to a composite gel 
which showed improved viscous characteristics compared 
to pure Pluronic® F127 gels, but with a small decrease in 
elastic behavior [60]. This thermosensitive gel may be 
used as an injectable hydrogel in tissue regeneration, for 
example [59, 60].
Carbon nanotubes (CNTs) can be used for modifica-
tion as well. They are rolled-up graphite sheets building 
single-walled (SWCNT) or multi-walled (MWCNT) hollow 
cylinders [61]. CNTs are interesting materials because of 
their unique mechanical and electrical properties [62]. 
They may be used as scaffolds for cardiac or neural tissue 
[63]. MacDonald et  al. showed that incorporation of 
SWCNT into a collagen hydrogel embedded with human 
dermal fibroblast cells led to a hydrogel with decreased 
gel compaction. The gel also exhibited electrical conduc-
tivity like native soft tissues [64]. Kim et al. demonstrated 
that the addition of SWCNT to collagen led to thicker fibers 
resulting in a less flexible matrix. Cultivation of human 
decidua parietalis placenta stem cells revealed no nega-
tive effects on cell proliferation and supported neural dif-
ferentiation [65].
The tensile strength of collagen can be further 
improved with functionalized silver nanoparticles 
[66] or curcumin-caged silver nanoparticles [67]. Both 
approaches resulted in a biocompatible network which 
enabled cells to proliferate and even inhibited microbial 
growth, making nanoparticle-functionalized collagen 
hydrogels promising candidates in wound dressing appli-
cations [66, 67].
The group of Tranquillo increased the stability of 
fibrin-based engineered tissue through a ruthenium-cata-
lyzed crosslinking system. This system leads to crosslinks 
between tyrosine residues of the fibrin and cell-deposited 
proteins, and resulted in a 3-fold increase in mechanical 
strength and a 10-fold increase in stiffness. These positive 
effects could be transferred to collagen-based engineered 
tissues [68].
Collagen and fibrin-based materials 
in vivo
Common medical applications of fibrin and collagen 
hydrogels are in the context of nerve regeneration, skin 
repair and cartilage tissue engineering. Even though some 
of these applications are typical for fibrin, as well as for 
collagen, the two proteins do not necessarily fulfill the 
same function in the preparation. Many fibrin dressings 
employ fibrin’s natural capacity for hemostasis and angi-
ogenesis. Collagen is mostly used as a bioactive scaffold 
Bereitgestellt von | Technische Informationsbibliothek Hannover
Angemeldet
Heruntergeladen am | 12.04.18 10:15
Schneider-Barthold et al.: Hydrogels based on collagen and fibrin      7
for cells or as a dressing for wound healing, which cor-
responds to its role in the ECM.
Various applications in biomedical research require 
higher mechanical strength than the one provided by the 
natural hydrogels themselves. Therefore, in the appli-
cations listed in Tables  1 and  2 the hydrogels have been 
compressed, crosslinked or blended with natural or 
synthetic polymers to enhance their mechanical proper-
ties. The resulting hydrogels are used in different in vivo 
environments.
Commercial products
Various products of fibrin and collagen are commercially 
available for clinical use. These include treatments for 
skin, nerves, vascular tissue and soft tissue. In contrast 
to the collagen and fibrin-based biomaterials which are 
the focus of current research, the commercial products 
of fibrin and collagen constitute mainly of isolates of the 
individual proteins. In current commercial applications, 
fibrin and collagen are used in their natural role as a 
hemostatic agent and an ECM protein, respectively.
Tisseel® was the first fibrinogen product approved 
by the US Food and Drug Administration (FDA). It has 
been marketed as a sealant for colonic anastomoses and 
as a hemostat when sutures or ligatures are ineffective 
to control bleeding since 1998 [79]. Since then, addi-
tional FDA-approved fibrinogen products have appeared 
on the market acting as hemostats, sealants and tissue 
adhesives in different clinical settings. Most of these com-
mercial applications mimic the last step of the coagula-
tion cascade, leading to the formation of a fibrin clot. The 
major differences between these medical devices are to 
be found in the source of fibrinogen and their application 
forms. Fibrinogen can be applied either in liquid or dried 
form. Liquid fibrin sealants are sprayed directly onto the 
wound, whereas dried fibrinogen is embedded into a solid 
matrix which is then placed onto the wound.
Examples for liquid fibrin include Tisseel®, Evicel® or 
Artiss®. Tisseel® and Evicel® are both assisting in hemo-
stasis but differ in their formulation [79, 80]. Both contain 
human fibrinogen and thrombin from pooled human 
Table 1: In vivo applications of fibrin hydrogels.
Form   Material   Application   References
Gel   Fibrin   Autologous blood vessel implant   [14]
  Fibrin-PEG   Vascular network formation   [51]
  Fibrin-hyaluronic acid   Scaffold for cartilage repair   [69]
  Fibrin-PVDF   Vascular graft   [70]
  Fibrin-PLA   Vascular graft   [71]
  Long-term stable fibrin-polycaprolactone- 
based polyurethane scaffold
  Cartilage engineering   [12]
Sponge   Fibrin-PLLA-PLGA   Regulation of 3D vessel formation 
and neovascularization
  [56]
PLLA, Poly(L-lactic acid); PLGA, polylactic-co-glycolic acid; PVDF, polyvinylidenfluorid.
Table 2: Examples of in vivo applications of collagen hydrogels.
Form   Material   Application   References
Disk   EDC-crosslinked collagen   Corneal substitute   [72]
Film   Collagen-poly(glutamic acid)   Surgical adhesive for damaged lungs  [73]
Gel   Collagen I (dehydro-thermally crosslinked)  Spinal cord repair   [74]
Matrix   Collagen-elastin   Skin wound coverage   [75]
Scaffold  Collagen I compressed   Artificial corneas   [76]
  Collagen II-glycosaminoglycan   Cartilage tissue engineering   [77]
  Collagen-chitosan   Peripheral nerve regeneration   [78]
  Collagen crosslinked with aminosilane 
functionalized silver nanoparticles
  Wound dressing   [66]
Sponge   Collagen-chitosan   Diabetic wound healing   [30]
EDC, 1-ethyl-3(-3-dimethylaminopropyl)carbodiimide.
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plasma. Tisseel® contains synthetic aprotinin as an adju-
vant to inhibit fibrinolysis [79]. Artiss®, however, differs 
from Tisseel® and Evicel® in its utilization, although it 
also contains homologous human fibrinogen and human 
thrombin. It is used as a tissue adhesive in the treatment 
of burned skin for the binding of autologous skin grafts. 
Furthermore, it can be applied in face-lifting procedures to 
adhere tissue flaps [81]. Most of these liquid formulations 
carry the disadvantage that they have to be stored cooled, 
whereas dried formulations are ready-to-use which makes 
them ideal for emergency cases.
In 2010, TachoSil® received approval of the FDA as 
the first fibrinogen patch. This patch contains an equine 
collagen sponge as a carrier matrix providing mechanical 
stability and flexibility. It is indicated in hepatic and cardi-
ovascular surgery to control bleeding [82]. Another patch 
(Evarrest®, Ethicon/J&J) is composed of layers of oxidized 
regenerated cellulose and polyglactin G910 which contain 
embedded fibrinogen and thrombin. It is used in liver sur-
geries or to stop soft tissue bleeding [83].
All previously mentioned products contain homol-
ogous fibrinogen and thrombin from pooled human 
plasma. These materials always carry the residual risk of 
containing blood-borne pathogens like viruses or prions 
and are highly dependent on blood donations. A different 
approach is the isolation of autologous fibrinogen from 
the patient’s own blood during or before surgery.
One possibility to get autologous fibrinogen is offered 
by the Vivostat® System. After blood withdrawal, a non-
physiological cleavage of the fibrinopeptide A is achieved 
by using the snake venom batroxobin. The resulting fibrin 
I polymer can be separated from blood plasma through 
centrifugation. This fibrin I network polymerizes into a 
fibrin clot by pH-adjustment which activates residual 
endogenous prothrombin, resulting in a cleavage of fibrin-
opeptide B and activation of endogenous Factor XIII [84]. 
The CryoSeal® FS System automates the cryoprecipitation 
step. The resulting fibrin sealant is indicated as a hemo-
stat in liver resection [85].
Dyna-Stat® and formerly CoStasis®, now Vitagel™, 
is an application system which contains a solution of 
bovine collagen and thrombin. A mixture of this solution 
with autologous blood plasma leads to a collagen/fibrin 
matrix [86].
Pure collagen gels can also be applied as hemostats. 
Several companies are producing collagen-based hemo-
stats as an alternative to manual compression [87, 88]. 
These are available as dry materials like powder, sheet, 
sponge, or as a sprayable liquid. Examples for dry mate-
rial products include Helistat® and Helitene® sponges, 
D-Stat® bandages and Avitene® powder or sheets.
Dermal wound dressings consisting of collagen 
are commonly used and present a different example of 
commercial translation. Apligraf® is one example of an 
artificial skin matrix used for venous leg ulcers and dia-
betic foot ulcers [89]. It consists of bovine type I collagen 
seeded with human fibroblasts in the lower dermal layer 
and human keratinocytes in the upper epidermal layer 
forming a skin-like structure. Alloderm® of LifeCell™ 
also started as a dermal dressing, but its main use has 
shifted towards reconstruction of soft tissues like breasts 
and abdominal organs. The biological matrix used in 
Alloderm® is decellularized human skin tissue which 
promotes a regenerative process after implantation. 
A similar effect is provided by the INTEGRA™ Matrix 
Wound Dressing which is composed of bovine tendon 
collagen type I and glycosaminoglycans. It can be com-
bined with INTEGRA™ Bilayer Matrix Wound Dressing 
for a flexible covering with water vapor loss control. 
Special treatment is necessary for the care of burned 
skin. Biobrane® of Smith & Nephew consists of porcine 
collagen and allows faster healing time than conven-
tional burn care [90]. It can also be used for the healing 
of transplanted skin.
Apart from dermal applications, collagen is also used 
for peripheral nerve regeneration, as for example, Neu-
raGen® from INTEGRA™. This collagen tube consists of 
crosslinked collagen which supports axonal growth across 
a nerve gap [91]. Another example of collagen application 
in nerve regeneration is DuraGen® from INTEGRA™. It 
consists of bovine Achilles tendon collagen type I and is 
used in cranial and spinal operations as a substitute of 
injured dura mater to prevent leakage of cerebrospinal 
fluid [92]. TissuDura of Baxter is a very similar but trans-
parent product made of equine collagen. It has the same 
application field and has shown comparable results in 
clinical application [93, 94].
Another application field of collagen is in the regen-
erative therapy of bone and cartilage. Matricel pro-
duces membranes consisting of porcine collagen which 
promote bone regeneration (Remaix) or cartilage regen-
eration (Cartimaix). The membrane functions as a barrier 
for the recovery area and as an adhesion site for cells. 
Thus, it can support the regeneration of the damaged 
tissue [95].
Conclusion and future perspectives
The challenge of designing a novel biomaterial is to 
provide an environment which closely resembles the 
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native tissue which has to be replaced. As the understand-
ing of the basic underlying mechanisms of ECM-cell inter-
actions becomes increasingly elucidated, we can expect 
that additional knowledge will flow into material design. 
Hydrogels with an ECM-like composition offer the best 
possibility to mimic native tissue and are the first step to 
accomplish structure and organization similar to native 
ECM.
Structural proteins like fibrin and collagen are a good 
starting point for creating ECM-based materials as they 
are already approved for clinical application. As pure col-
lagen and fibrin hydrogels show poor mechanical stabil-
ity, major advances have been made in the development 
of modified and functionalized biomaterials. Modification 
with additional proteins, polysaccharides or synthetic 
polymers has led to hydrogels with improved stability for 
various tissue regeneration procedures.
Due to the fact that collagen and fibrinogen are 
usually extracted from biological sources, batch-to-batch 
variations will invariably appear which could hinder the 
GMP requirements for a particular product. A more secure 
way to obtain pure proteins of consistent quality and free 
of the risk of pathogenic transmission is recombinant 
production. Most heterologous expression systems for 
fibrinogen production are based on mammalian cells (e.g. 
baby hamster kidney cells [96] or PER.C6 cells [97]) due 
to the complex structure and post-translational modifica-
tions involved. Furthermore, fibrinogen could be isolated 
from the milk of transgenic dairy cows [98]. In contrast 
to fibrin, recombinant collagen production has been suc-
cessfully demonstrated in yeast systems [99]. Stein et al. 
could prove that production of collagen type I is also pos-
sible in tobacco plants [100].
Another strategy for obtaining novel ECM-based mate-
rials involves the production of tailor-made proteins with 
characteristic sequences of interest to create fibrin and col-
lagen-mimetic recombinant materials. These protein frag-
ments could be produced with simple and cost-effective 
expression systems like Escherichia coli or Pichia pastoris.
The next level of design of collagen and fibrin-based 
biomaterials includes considerations of the fabrication 
technique which allows the manufacture of complex 
3D structures with defined geometry and architecture. 
Techniques like stereolithography, micro-molding, bio-
printing, and laser structuring require bioactive materi-
als which can be quickly polymerized using changes in 
temperature, enzymatic or light reactions. In this way, it is 
possible to structure the physiological environment pro-
vided by the hydrogel into precise micro-scale structures, 
which is a major step towards the engineering of artificial 
3D tissues and organs.
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